Research Article
BibTex RIS Cite

“Double test screening values: Are they different in IVF and spontaneous pregnancies ?”

Year 2019, Volume: 4 Issue: 2, 53 - 59, 25.12.2019

Abstract

Objective:  To compare the IVF pregnancy group and
spontaneous pregnancy group in terms of PAPP-A and free β-hCG

Materials and methods:

 Among the pregnant women who applied for
double test screening between September 2017 and September 2018, 42 singleton
pregnancies that were pregnant as a result of IVF (in vitro fertilization)
constituted our study group where 109 singleton pregnancies whose age range
were matching the IVF pregnacies but were pregnant spontaneously without any
assisted reproductive technologies (ART) remained in our control group. The
demographic data and pregnancy outcomes of both pregnancies were similar.

Findings:

The mean PAPP-A (pregnancy
associated plasma protein-A) was found in the control group (2.82 mlU / ml;
0.97 MoM), while in the study group 2.41 mlU / ml, 0.94 MoM). Free β-hCG
(beta-human chorionic gonadotropin) values were found as 46.44, ng / ml;
1.21MoM, 53.79ng / ml in control and study groups respectively. The mean PAPP-A
of the IVF pregnancy group was lower than the spontaneous pregnancy group, and
the mean β-hCG was higher than the spontaneous pregnancy group, but these
differences were not statistically significant (p> 0.005). Although not
statistically significant; In terms of trisomy 21 we evaluated the study group
as higher risk than the control group (p> 0.05).











Results: The mean of PAPP-A
and free β-hCG values are different in IVF and spontaneous pregnancies, and
these differences in biochemical parameters affect the risk of trisomy 21.

References

  • References:
  • 1.Pakniat H, Bahman A, Ansari I. The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study. J Obstet Gynaecol India. 2019; Oct;69(5):412-419.2. Gagnon A, Wilson RD; Society of Obstetricians and Gynaecologists of Canada Genetic Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008 ;Oct;30(10):918-932.3.Cignini P, Maggio Savasta L, Gulino FA, et al. Predictive value of pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG on fetal growth restriction: results of a prospective study. Arch Gynecol Obstet. 2016; Jun;293(6):1227-33.4. Zhong Y, Bradshaw R, Stanley AP, Odibo AO. The impact of assisted reproductive technology on the association between first-trimester pregnancy-associated plasma protein a and human chorionic gonadotropin and adverse pregnancy outcomes. Am J Perinatol. 2011; May;28(5):347-545. Smith GCS, Stenhouse EJ, Crossley JA et al. Early Pregnancy Levels of Pregnancy Associated Plasma Protein A and the Risk of Intrauterine Growth Restriction, Premature Birth, Preeclampsia, and Stillbirth. J Clin Endocrinol Metab, April 2002; 87(4):1762–17676. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy associated plasma protein. A Ultrasound Obstet Gynecol 2008; 31:618-24.7. Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18 N Engl J Med 2003; 349-15:1405-13.8.Cell-free DNA screening for fetal aneuploidy. Committee Opinion No. 640. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126(3):e31–79. Leung TY, Sahota DS, Chan LW, Law LW, Fung TY, Leung TN, Lau TK. Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-A in the first trimester. Ultrasound Obstet Gynecol. 2008 Jan;31(1):10-410.Rudenko G, Hohenester E, Muller YA.LG/LNS domains: multiple functions – one business end? Trends Biochem. Sci. 26 ;2001; 363–368.11.Ong Cy, Liao Aw, Spencer K et al. First trimestr maternal serum free bet human chorionic gonadotrophin and pregnancy asociated plasma protein A as a predictors of pregnancy complications. BJOG 2000; 107:1265-70.12. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-brid- ged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243—12246.13.Brambati B, Lanzani A, Tului L. Ultrasound and biochemical assessment of first trimester of pregnancy. 181—194. In: Chapman M, Gru- dzinskas G, Chard T (Eds): The Embryo: Normal and Abnormal Deve- lopment and Growth. London, Springer Verlag 1990. 4014. Overgaard MZ, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M et al: Expression of recombinant human pregnancy-associa- ted plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem 2000; 275: 31126—31133.15. Bode W, Grams F, Reinemer P, Gomis-Ruth FX, Baumann U, Mc- Kay DB, Stockler W. The metzincin-superfamily of zinc-peptidases. Adv Exp Med Biol 1996; 89: 1-11.16.Kristensen T, Oxvig C, Sand O et al. Amino acid sequence of human pregnancyassociated plasma protein-A derived from cloned cDNA, Biochemistry 33 (1994) 1592– 1598. 17.Haaning J, Oxvig C, Overgaard MT et al. Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A: evidence for expressionin the brain and inductionby cAMP, Eur. J. Biochem.1996; 237, 159–163. 18.Boldt HB, Glerup S, Overgaard MT et al. Definition, expression, and characterization of a protein domain in the N-terminus of pregnancy-associated plasma pro-tein-A distantly related to the family of laminin G-like models, Protein Expr. Purif. 48 ,2006; 261–273.19. Francesco O, Cinzia R, A. Allegra, David K, Terrence H, Emanuela O, James M. First trimester screening with free B-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenatal Diagnosis.2002; 22: 718-72120. Marko N. First trimester screening for down syndrome. Department of Obstetrics and Gynaecology University of Oulu. Acta Univ. Oul. D 727, 2003; 5: 35-41. (URL: http://herkules.oulu.fi/isbn9514270290/)21.Robabeh T, Maryam T, Donya K, Hamed T. Comparison of free beta-HCG and PAPP-A at 12 weeks of gestational age between single pregnancies after spontaneous conception and after IVF treatment. Med Crave. 2017; 8 : 122. Engels MA, Pajkrt E, Groot DT, Schats R, Twisk JW, et al. Validation of correction factors for serum markers for first-trimester Down syndrome screening in singleton pregnancies conceived with assisted reproduction. Fetal Diagn Ther .2013;34(4): 217-224.23. Cavoretto P, Giorgione V, Cipriani S, Viganò P, Candiani M, et al. Nuchal translucency measurement, free β‐hCG and PAPP‐A concentrations in IVF/ICSI pregnancies: systematic review and meta‐analysis. Prenat Diagn.2017; 37(6): 540-555.24. Savasi VM, Mandia L, Laoreti A, Ghisoni L, Duca P, et al. First trimester placental markers in oocyte donation pregnancies. Placenta .2015;36(8): 921-925.25.Smith R, Bischof P, Hughes G, Klopper A. Studies on pregnancy- associated plasma protein A in the third trimester of pregnancy. Brit J Obstet Gynaecol.1979; 86: 882— 887.
Year 2019, Volume: 4 Issue: 2, 53 - 59, 25.12.2019

Abstract

References

  • References:
  • 1.Pakniat H, Bahman A, Ansari I. The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study. J Obstet Gynaecol India. 2019; Oct;69(5):412-419.2. Gagnon A, Wilson RD; Society of Obstetricians and Gynaecologists of Canada Genetic Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008 ;Oct;30(10):918-932.3.Cignini P, Maggio Savasta L, Gulino FA, et al. Predictive value of pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG on fetal growth restriction: results of a prospective study. Arch Gynecol Obstet. 2016; Jun;293(6):1227-33.4. Zhong Y, Bradshaw R, Stanley AP, Odibo AO. The impact of assisted reproductive technology on the association between first-trimester pregnancy-associated plasma protein a and human chorionic gonadotropin and adverse pregnancy outcomes. Am J Perinatol. 2011; May;28(5):347-545. Smith GCS, Stenhouse EJ, Crossley JA et al. Early Pregnancy Levels of Pregnancy Associated Plasma Protein A and the Risk of Intrauterine Growth Restriction, Premature Birth, Preeclampsia, and Stillbirth. J Clin Endocrinol Metab, April 2002; 87(4):1762–17676. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy associated plasma protein. A Ultrasound Obstet Gynecol 2008; 31:618-24.7. Wapner R, Thom E, Simpson JL, et al. First-trimester screening for trisomies 21 and 18 N Engl J Med 2003; 349-15:1405-13.8.Cell-free DNA screening for fetal aneuploidy. Committee Opinion No. 640. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126(3):e31–79. Leung TY, Sahota DS, Chan LW, Law LW, Fung TY, Leung TN, Lau TK. Prediction of birth weight by fetal crown-rump length and maternal serum levels of pregnancy-associated plasma protein-A in the first trimester. Ultrasound Obstet Gynecol. 2008 Jan;31(1):10-410.Rudenko G, Hohenester E, Muller YA.LG/LNS domains: multiple functions – one business end? Trends Biochem. Sci. 26 ;2001; 363–368.11.Ong Cy, Liao Aw, Spencer K et al. First trimestr maternal serum free bet human chorionic gonadotrophin and pregnancy asociated plasma protein A as a predictors of pregnancy complications. BJOG 2000; 107:1265-70.12. Oxvig C, Sand O, Kristensen T, Gleich GJ, Sottrup-Jensen L. Circulating human pregnancy-associated plasma protein-A is disulfide-brid- ged to the proform of eosinophil major basic protein. J Biol Chem 1993; 268: 12243—12246.13.Brambati B, Lanzani A, Tului L. Ultrasound and biochemical assessment of first trimester of pregnancy. 181—194. In: Chapman M, Gru- dzinskas G, Chard T (Eds): The Embryo: Normal and Abnormal Deve- lopment and Growth. London, Springer Verlag 1990. 4014. Overgaard MZ, Haaning J, Boldt HB, Olsen IM, Laursen LS, Christiansen M et al: Expression of recombinant human pregnancy-associa- ted plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. J Biol Chem 2000; 275: 31126—31133.15. Bode W, Grams F, Reinemer P, Gomis-Ruth FX, Baumann U, Mc- Kay DB, Stockler W. The metzincin-superfamily of zinc-peptidases. Adv Exp Med Biol 1996; 89: 1-11.16.Kristensen T, Oxvig C, Sand O et al. Amino acid sequence of human pregnancyassociated plasma protein-A derived from cloned cDNA, Biochemistry 33 (1994) 1592– 1598. 17.Haaning J, Oxvig C, Overgaard MT et al. Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A: evidence for expressionin the brain and inductionby cAMP, Eur. J. Biochem.1996; 237, 159–163. 18.Boldt HB, Glerup S, Overgaard MT et al. Definition, expression, and characterization of a protein domain in the N-terminus of pregnancy-associated plasma pro-tein-A distantly related to the family of laminin G-like models, Protein Expr. Purif. 48 ,2006; 261–273.19. Francesco O, Cinzia R, A. Allegra, David K, Terrence H, Emanuela O, James M. First trimester screening with free B-hCG, PAPP-A and nuchal translucency in pregnancies conceived with assisted reproduction. Prenatal Diagnosis.2002; 22: 718-72120. Marko N. First trimester screening for down syndrome. Department of Obstetrics and Gynaecology University of Oulu. Acta Univ. Oul. D 727, 2003; 5: 35-41. (URL: http://herkules.oulu.fi/isbn9514270290/)21.Robabeh T, Maryam T, Donya K, Hamed T. Comparison of free beta-HCG and PAPP-A at 12 weeks of gestational age between single pregnancies after spontaneous conception and after IVF treatment. Med Crave. 2017; 8 : 122. Engels MA, Pajkrt E, Groot DT, Schats R, Twisk JW, et al. Validation of correction factors for serum markers for first-trimester Down syndrome screening in singleton pregnancies conceived with assisted reproduction. Fetal Diagn Ther .2013;34(4): 217-224.23. Cavoretto P, Giorgione V, Cipriani S, Viganò P, Candiani M, et al. Nuchal translucency measurement, free β‐hCG and PAPP‐A concentrations in IVF/ICSI pregnancies: systematic review and meta‐analysis. Prenat Diagn.2017; 37(6): 540-555.24. Savasi VM, Mandia L, Laoreti A, Ghisoni L, Duca P, et al. First trimester placental markers in oocyte donation pregnancies. Placenta .2015;36(8): 921-925.25.Smith R, Bischof P, Hughes G, Klopper A. Studies on pregnancy- associated plasma protein A in the third trimester of pregnancy. Brit J Obstet Gynaecol.1979; 86: 882— 887.
There are 2 citations in total.

Details

Primary Language Turkish
Journal Section Original Research
Authors

Ömür Keskin This is me 0000-0001-7602-3565

Murat Alan This is me 0000-0002-9108-2990

Yasemin Alan 0000-0003-2680-814X

Emrah Töz 0000-0002-3730-357X

Publication Date December 25, 2019
Submission Date October 21, 2019
Published in Issue Year 2019 Volume: 4 Issue: 2

Cite

APA Keskin, Ö., Alan, M., Alan, Y., Töz, E. (2019). “Double test screening values: Are they different in IVF and spontaneous pregnancies ?”. Samsun Sağlık Bilimleri Dergisi, 4(2), 53-59.
AMA Keskin Ö, Alan M, Alan Y, Töz E.“Double test screening values: Are they different in IVF and spontaneous pregnancies ?.” JSHS. December 2019;4(2):53-59.
Chicago Keskin, Ömür, Murat Alan, Yasemin Alan, and Emrah Töz. “‘Double Test Screening Values: Are They Different in IVF and Spontaneous Pregnancies ?’”. Samsun Sağlık Bilimleri Dergisi 4, no. 2 (December 2019): 53-59.
EndNote Keskin Ö, Alan M, Alan Y, Töz E (December 1, 2019) “Double test screening values: Are they different in IVF and spontaneous pregnancies ?”. Samsun Sağlık Bilimleri Dergisi 4 2 53–59.
IEEE Ö. Keskin, M. Alan, Y. Alan, and E. Töz, “‘Double test screening values: Are they different in IVF and spontaneous pregnancies ?’”, JSHS, vol. 4, no. 2, pp. 53–59, 2019.
ISNAD Keskin, Ömür et al. “‘Double Test Screening Values: Are They Different in IVF and Spontaneous Pregnancies ?’”. Samsun Sağlık Bilimleri Dergisi 4/2 (December 2019), 53-59.
JAMA Keskin Ö, Alan M, Alan Y, Töz E. “Double test screening values: Are they different in IVF and spontaneous pregnancies ?”. JSHS. 2019;4:53–59.
MLA Keskin, Ömür et al. “‘Double Test Screening Values: Are They Different in IVF and Spontaneous Pregnancies ?’”. Samsun Sağlık Bilimleri Dergisi, vol. 4, no. 2, 2019, pp. 53-59.
Vancouver Keskin Ö, Alan M, Alan Y, Töz E. “Double test screening values: Are they different in IVF and spontaneous pregnancies ?”. JSHS. 2019;4(2):53-9.

22657

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).